Corporate Support
Sitemap

Features

Customer Services

Events

Terms of Use

Singapore
Malaysia

ShareInvestor.com

Mobile Edition
Mode - Streaming
Switch to Static Mode?

Price Highlight

Index Highlight

Chart
STI
3,122.6
-13.4 (-0.43%)

 

  • STI Straits Times Index
    3,122.6
    -13.4 (-0.43%)
     
  • KLCI FTSE Bursa Malaysia KLCI
    1,594.6
    -8.2 (-0.51%)
    Index delayed 15 minutes
  • HSI Hang Seng Index
    26,270.0
    38.5 (0.15%)
    Index delayed 15 minutes
  • SSE SSE Composite Index
    2,880.3
    0.3 (0.01%)
    Index delayed 15 minutes
  • N225 Nikkei 225
    20,618.6
    -58.7 (-0.28%)
    Index delayed 20 minutes
  • JCI Jakarta Composite Index
    6,253.0
    -42.8 (-0.68%)
    Index delayed 10 minutes
  • KOR KOSPI
    1,964.7
    4.4 (0.22%)
    Index delayed 20 minutes
  • XAO XAO
    6,572.6
    -54.8 (-0.83%)
     

SGX Market

Bursa Market

HKEx Market

SET Market

IDX Market

ASX Market

NYSE Market

NASDAQ Market

NYSE American Market

  • Volume: 692.8M
  • Value: 977.8M
  • Rise: 147
  • Fall: 136
  • Unch: 553

Intraday Market Ticker Help

Intraday Market Ticker
Time Name Type Price Vol

  • Top Active

  • Top Gainer

  • Top Loser

Top Counters
Name Last Change
ThaiBev0.925+0.035
YZJ Shipbldg SGD0.965-0.005
Spackman0.013-0.002
ESR-REIT0.520+0.010
Y Ventures0.101+0.008
Synagie0.168+0.008
Rex Intl0.077+0.001
SingTel3.190-0.030
Mapletree Com Tr2.080+0.010
Ascott Reit1.290-0.010

World Indices

World Indices
Name Last Change
Nasdaq 7,948.6 -54.2
HSI 26,270.0 +38.5
HSCEI 10,177.3 +44.5
Jakarta 6,253.0 -42.8
Nikkei 225 20,618.6 -58.6
SSE Comp 2,880.3 +0.3
Shanghai A 3,017.4 +0.3
Shanghai B 264.8 +0.2
PSE Comp 0.0
KOSPI 1,964.7 +4.4

Asian Indices delayed. US Indices updated twice daily at 7:30am and 7:30pm.

Fundamental - Factsheet

Help

  • Factsheet

  • Print

CSL CSL
Updated on 21 Aug 2019 (End of trading day)
Last (AUD): 235.300 Change: +0.850 High: 235.385 Remarks: -
Change (%): +0.36 Low: 232.085
Open 234.450 Yesterday's Close 234.45000000000002
Buy Price - Sell Price -
Buy Volume (share) - Sell Volume (share) -
Cumulative Volume (share) 683,111 Cumulative Value
 
Click to show Stock Prices chart

Key Statistics

EPS (AUD) a 5.92075 Trailing EPS (AUD) e 5.92075 NAV (AUD) b 16.5140
PE a 39.742 Trailing PE f 39.742 Price / NAV b 14.2485
Dividend (AUD) d 2.678861 Cash In Hand (AUD) g 2.0686 Issued & Paid-up Shares c 453,139,000
Dividend Yield (%) d 1.138 Price / Cash In Hand g 113.748 Treasury Shares h -
Beta - 75 Daysi 1.323 R-Squared - 75 Days(%)i 41.12 Market Cap (M) 106,623.607
Beta - 500 Daysi 1.267 R-Squared - 500 Days (%)i 34.86 Enterprise Value (M) 112,330.768
Piotroski F Score 4 Exchange Code CSL Par Value ( AUD ) n.a.
52 Weeks Volatility (%) 22.83 Free Float (%) 99.8
Sector & Industry Health Technology - Biotechnology
Notes:
  1. Based on latest Full Year results announcement, adjusted for the current number of shares.
  2. Based on latest results announcement (Full Year, Half Year or Interim), adjusted for carrying value of "Other Share Capital", illustrative financial effects of corporate actions (if applicable) and the current number of shares.
  3. Rounded to the nearest thousand. Updated on 05 Jun 2019.Please click here for more information.
  4. Dividend is based on latest Full Year results announcement, adjusted for current number of shares and excludes special dividend.
  5. Summation of the earnings from the latest 4 Quarter (or 2 Half Year) results announcement, adjusted for the current number of shares.
  6. Based on Trailing EPS.
  7. Based on reported cash and cash equivalents at end and extracted from the latest results announcement (Full Year, Half Year or Interim), adjusted for the current number of shares.
  8. Rounded to the nearest thousand. Updated on 16 Jul 2015.
  9. Beta and R-Squared are calculated in relation to the market index using the historical daily closing values of the stock and index as data points.

Peer Comparison

Type Name Market Market Cap (M)a PE b Trailing PE c Price / NAV d Dividend Yield (%)d
Reference CSL ASX 106,623.607 39.742 39.742 14.2485 1.138
Industry Biotechnology ASX 2,144.586 47.041 48.684 12.7804 1.089
Local Peer IMUGENE LIMITED ASX 72.197 - - 2.3256 -
Local Peer ORTHOCELL LIMITED ASX 60.951 - - 22.5714 -
Local Peer RHINOMED LIMITED ASX 43.999 - - 5.6261 -
Local Peer ONCOSIL MEDICAL LIMITED ASX 39.735 - - 2.9439 -
Local Peer PATRYS LIMITED ASX 24.133 - - 2.8846 -
Local Peer PROTEOMICS INTL LABORATORIES LTD ASX 22.189 - - 6.5476 -
Local Peer REGENEUS LTD ASX 21.017 - - -6.6957 -
Local Peer BIONOMICS LTD ASX 20.152 - - 1.2092 -
Local Peer IMMURON LIMITED ASX 19.446 - - 2.7094 -
Local Peer ANTEO DIAGNOSTICS LIMITED ASX 20.920 - - 8.2353 -
Local Peer CELLMID LIMITED ASX 17.976 - - 2.1984 -
Local Peer PRESCIENT THERAPEUTICS LIMITED ASX 15.770 - - 1.9802 -
Other Local Peers BENITEC BIOPHARMA LTD (ASX), HOLISTA COLLTECH LIMITED (ASX), BIOXYNE LIMITED (ASX), LIVING CELL TECHNOLOGIES (ASX), GENETIC TECHNOLOGIES (ASX), ANATARA LIFESCIENCES LTD (ASX), ACTINOGEN MEDICAL LTD (ASX), CCP TECHNOLOGIES LTD (ASX), TBG DIAGNOSTICS LTD (ASX), NANOLLOSE LTD (ASX), AVECHO BIOTECHNOLOGY LTD (ASX), NOVITA HEALTHCARE LTD (ASX), MEDIBIO LIMITED (ASX), AMPLIA THERAPEUTICS LTD (ASX), FACTOR THERAPEUTICS LIMITED (ASX), BPH ENERGY LIMITED (ASX), ALCHEMIA LIMITED (ASX), GENERA BIOSYSTEMS LIMITED (ASX)
Global Peer AMGEN INC NASDAQ 121,841.252 14.515 15.311 11.2878 2.728
Global Peer GILEAD SCIENCES INC NASDAQ 80,343.588 14.728 13.492 3.5525 3.638
Global Peer AMGEN-T HKEx 599,701.000 9.116 9.612 7.1115 4.345
Global Peer CELGENE CORP NASDAQ 67,514.668 16.687 12.809 6.7172 -
Global Peer VERTEX PHARMACEUTICAL NASDAQ 47,222.470 22.526 21.320 9.3142 -
Global Peer BIOGEN INC NASDAQ 42,658.902 9.628 8.058 3.2934 -
Global Peer ILLUMINA INC NASDAQ 41,843.550 50.658 44.609 9.6592 -
Global Peer REGENERON PHARMACEUTICALS INC NASDAQ 32,532.024 13.309 15.722 3.3346 -
Global Peer ALEXION PHARMACEUTICAL INC NASDAQ 24,985.615 321.978 18.735 2.4584 -
Global Peer AGILENT TECHNOLOGIES INC NYSE 22,473.422 71.119 20.964 4.7342 0.843
Other Global Peers INCYTE CORPORATION (NASDAQ), SINO BIOPHARM (HKEx), EXACT SCIENCES CORP (NASDAQ), BIOMARIN PHARMACEUTICAL (NASDAQ), SEATTLE GENETICS INC (NASDAQ), WUXI BIO (HKEx), IONIS PHARMACEUTICALS INC (NASDAQ), GALAPAGOS NV SPON ADR REPR 1 ORD SHS (NASDAQ), ALNYLAM PHARMACEUTICALS INC (NASDAQ), NEUROCRINE BIOSCIENCES INC (NASDAQ), SAREPTA THERAPEUTICS INC (NASDAQ), BEIGENE (HKEx), BEIGENE LTD SPON ADS EACH REPR 13 ORD SHS (NASDAQ), BIO-TECHNE CORP (NASDAQ), EXELIXIS INC (NASDAQ), BLUEBIRD BIO INC (NASDAQ), ASCENDIS PHARMA A/S SPON ADR EACH REP 1 ORD SHS (NASDAQ), REPLIGEN CORP (NASDAQ), MODERNA INC (NASDAQ), GENSCRIPT BIO (HKEx), Lonza (SGX), ACADIA PHARMACEUTICALS INC (NASDAQ), 3SBIO (HKEx), BLUEPRINT MEDICINES CORP (NASDAQ), FIBROGEN INC (NASDAQ), MORPHOSYS SPON ADS EACH REP 0.25 ORD SHS (NASDAQ), SPARK THERAPEUTICS INC (NASDAQ), CHINA BIOLOGIC PRODUCTS HLDGS INC (NASDAQ), MIRATI THERAPEUTICS INC (NASDAQ), ALKERMES PLC (NASDAQ), ULTRAGENYX PHARMACEUTICAL INC (NASDAQ), ALLOGENE THERAPEUTICS INC (NASDAQ), ARROWHEAD PHARMACEUTICALS INC (NASDAQ), NEKTAR THERAPEUTICS (NASDAQ), TILRAY INC (NASDAQ), GLOBAL BLOOD THERAPEUTICS INC (NASDAQ), IMMUNOMEDICS INC (NASDAQ), ARENA PHARMACEUTICALS INC (NASDAQ), GENOMIC HEALTH INC (NASDAQ), PTC THERAPEUTICS INC (NASDAQ), AMICUS THERAPEUTICS INC (NASDAQ), CRISPR THERAPEUTICS AG (NASDAQ), AGIOS PHARMACEUTICALS INC (NASDAQ), IOVANCE BIOTHERAPEUTICS INC (NASDAQ), ACCELERON PHARMA (NASDAQ), HALOZYME THERAPEUTICS INC (NASDAQ), XENCOR INC (NASDAQ), EMERGENT BIOSOLUTIONS INC (NYSE), ZAI LAB LIMITED ADS EACH REP 1 ORD SHS (NASDAQ), UNIQURE N.V. (NASDAQ), NATERA INC (NASDAQ), MYRIAD GENETICS INC (NASDAQ), LIGAND PHARMACEUTICAL INC (NASDAQ), DENALI THERAPEUTICS INC (NASDAQ), DECIPHERA PHARMACEUTICALS INC (NASDAQ), EIDOS THERAPEUTICS INC (NASDAQ), AUDENTES THERAPEUTICS INC (NASDAQ), INSMED INC (NASDAQ), ENANTA PHARMACEUTICALS INC (NASDAQ), HERON THERAPEUTICS INC (NASDAQ), REGENXBIO INC (NASDAQ), COHERUS BIOSCIENCES INC (NASDAQ), SANGAMO THERAPEUTICS INC (NASDAQ), AIMMUNE THERAPEUTICS INC (NASDAQ), ANAPTYSBIO INC (NASDAQ), EDITAS MEDICINE INC (NASDAQ), EPIZYME INC (NASDAQ), OPKO HEALTH INC (NASDAQ), FATE THERAPEUTICS (NASDAQ), MOMENTA PHARMACEUTICALS INC (NASDAQ), VERACYTE INC (NASDAQ), INTREXON CORP (NASDAQ), CARA THERAPEUTICS INC (NASDAQ), ALECTOR INC (NASDAQ), RADIUS HEALTH INC (NASDAQ), ESPERION THERAPEUTICS INC (NASDAQ), STOKE THERAPEUTICS INC (NASDAQ), OMEROS CORP (NASDAQ), NANOSTRING TECHNOLOGIES INC (NASDAQ), NGM BIOPHARMACEUTICALS INC (NASDAQ), TWIST BIOSCIENCE CORPORATION (NASDAQ), DICERNA PHARMACEUTICALS INC. (NASDAQ), LUMINEX CORP(DEL) (NASDAQ), FRONTAGE (HKEx), PACIFIC BIOSCIENCES CALIFORNIA INC (NASDAQ), RUBIUS THERAPEUTICS INC (NASDAQ), SPECTRUM PHARMACEUTICALS INC (NASDAQ), INTELLIA THERAPEUTICS INC (NASDAQ), ZIOPHARM ONCOLOGY INC (NASDAQ), ADVERUM BIOTECHNOLOGIES INC (NASDAQ), CYTOKINETICS INC (NASDAQ), VANDA PHARMACE INC (NASDAQ), ALDER BIOPHARMACEUTICALS INC (NASDAQ), KURA ONCOLOGY INC (NASDAQ), ARVINAS INC (NASDAQ), VOYAGER THERAPEUTICS INC (NASDAQ), MEIRAGTX HOLDINGS PLC (NASDAQ), HOMOLOGY MEDICINES INC (NASDAQ), RETROPHIN INC (NASDAQ), ATARA BIOTHERAPEUTICS INC (NASDAQ), HAOHAI BIOTEC (HKEx), VIVA BIOTECH (HKEx), WAVE LIFE SCIENCES LTD (NASDAQ), MACROGENICS INC (NASDAQ), STEMLINE THERAPEUTICS INC (NASDAQ), RHYTHM PHARMACEUTICALS INC (NASDAQ), CORTEXYME INC (NASDAQ), MYOVANT SCIENCES LTD (NYSE), UROGEN PHARMA LTD (NASDAQ), MORPHIC HOLDING INC (NASDAQ), DBV TECHNOLOGIES SPON ADR EACH REPR 0.5 ORD (NASDAQ), ZEALAND PHARMA AS SPON ADR EACH REP 1 ORD SHS (NASDAQ), GENFIT SPON ADS EACH REP 1 ORD SHS (NASDAQ), ACHILLION PHARMACEUTICALS INC (NASDAQ), TG THERAPEUTICS INC (NASDAQ), AVROBIO INC (NASDAQ), NEXTCURE INC (NASDAQ), PERSONALIS INC (NASDAQ), ASCLETIS-B (HKEx), AKEBIA THERAPEUTICS INC (NASDAQ), KARYOPHARM THERAPEUTICS INC (NASDAQ), ROCKET PHARMACEUTICALS INC (NASDAQ), SYNTHORX INC (NASDAQ), CELLECTIS ADS EACH REPR 1 ORD SPON (NASDAQ), INTRA-CELLUAR THERAPIES INC (NASDAQ), VIKING THERAPEUTICS INC (NASDAQ), MESOBLAST LTD SPON ADR EACH REP 5 SHS (NASDAQ), PRECISION BIOSCIENCES INC (NASDAQ), AUTOLUS THERAPEUTICS PLC SPON ADS EA REP 1 ORD SHS (NASDAQ), SYROS PHARMACEUTICALS INC (NASDAQ), AURINIA PHARMACEUTICALS INC (NASDAQ), CKLIFE SCIENCES (HKEx), DERMIRA INC (NASDAQ), MAGENTA THERAPEUTICS INC (NASDAQ), SINOVAC BIOTECH (NASDAQ), CYTOMX THERAPEUTICS INC (NASDAQ), MERUS B V (NASDAQ), MERIDIAN BIOSCIENCE INC COM (NASDAQ), SOLID BIOSCIENCES INC (NASDAQ), IMMUNOGEN INC (NASDAQ), KODIAK SCIENCES INC (NASDAQ), FLEXION THERAPEUTICS INC (NASDAQ), TRANSLATE BIO INC (NASDAQ), CHEMOCENTRYX INC (NASDAQ), NEPTUNE WELLNESS SOLUTIONS INC (NASDAQ), PUMA BIOTECHNOLOGY INC (NASDAQ), MEDICINOVA INC (NASDAQ), CYMABAY THERAPEUTICS INC (NASDAQ), AGENUS INC (NASDAQ), ESSEX BIO-TECH (HKEx), STEALTH BIOTHERAPEUTICS CORP SPON ADS EACH REP 12 ORD SHS (NASDAQ), AVID BIOSERVICES INC (NASDAQ), PREVAIL THERAPEUTICS INC (NASDAQ), CORBUS PHARMACEUTICALS HOLDINGS IN (NASDAQ), RESTORBIO INC (NASDAQ), XBIOTECH INC (NASDAQ), REPLIMUNE GROUP INC (NASDAQ), SCHOLAR ROCK HOLDING CORPORATION (NASDAQ), PROQR THERAPEUTICS N V (NASDAQ), RIGEL PHARMACEUTICALS INC (NASDAQ), KADMON HLDGS INC (NYSE), ARCUS BIOSCIENCES INC (NYSE), CLOVIS ONCOLOGY INC (NASDAQ), BIOFRONTERA AG SPON ADS EACH REP TWO ORD SHS (NASDAQ), PROTHENA CORP PLC (NASDAQ), CASI PHARMACEUTICALS INC (NASDAQ), PROGENICS PHARMACEUTICALS INC (NASDAQ), SORRENTO THERAPEUTICS INC (NASDAQ), BIOCRYST PHARMACEUTICALS INC (NASDAQ), PROTAGONIST THERAPEUTICS INC (NASDAQ), PDL BIOPHARMA INC (NASDAQ), HARPOON THERAPEUTICS INC (NASDAQ), DYNAVAX TECHNOLOGIES CORP (NASDAQ), SYNDAX PHARMACEUTICALS INC (NASDAQ), NUCANA PLC SPON ADR EACH REP 1 ORD SHS (NASDAQ), LA JOLLA PHARMACEUTICAL CO (NASDAQ), LEE'S PHARM (HKEx), GERON CORP (NASDAQ), NEUROINSIGHTS NEUROTECH (NASDAQ), UNITY BIOTECHNOLOGY INC (NASDAQ), EIGER BIOPHARMACEUTICALS INC (NASDAQ), RECRO PHARMA INC (NASDAQ), CONCERT PHARMACEUTICALS INC (NASDAQ), ELOXX PHARMACEUTICALS INC (NASDAQ), ADMA BIOLOGICS INC (NASDAQ), CELLULAR BIOMEDICINE GROUP INC (NASDAQ), COMPUGEN (NASDAQ), PIERIS PHARMACEUTICALS INC (NASDAQ), SERES THERAPEUTICS (NASDAQ), XENON PHARMACEUTICALS INC (NASDAQ), EVOFEM BIOSCIENCES INC (NASDAQ), MANNKIND CORPORATION (NASDAQ), CALITHERA BIOSCIENCES INC (NASDAQ), DPHARMA (Bursa), KAMADA (NASDAQ), FIVE PRIME THERAPEUTICS (NASDAQ), CHIASMA INC (NASDAQ), ATHERSYS INC (NASDAQ), REDHILL BIOPHARMA LTD SPON ADS EA REPR 10 ORD ILS0.00 (NASDAQ), 22ND CENTURY GROUP INC (NYSE American), GALECTIN THERAPEUTICS INC (NASDAQ), MOLECULAR TEMPLATES INC (NASDAQ), CUE BIOPHARMA INC (NASDAQ), ARDELYX INC (NASDAQ), AXCELLA HEALTH INC (NASDAQ), ADAPTIMMUNE THERAPEUTICS PLC ADS EACH REPR 6 SHS (SPONS) (NASDAQ), DYADIC INTERNATIONAL INC (NASDAQ), AFFIMED N V (NASDAQ), NOVAVAX INC (NASDAQ), TAIWAN LIPOSOME COMPANY LTD SPON ADS EACH REP 2 ORD SHS (NASDAQ), APPLIED THERAPEUTICS INC (NASDAQ), PFENEX INC (NYSE American), NABRIVA THERAPEUTICS PLC (NASDAQ), X4 PHARMACEUTICALS INC (NASDAQ), CHIMERIX INC (NASDAQ), XOMA CORP (NASDAQ), AXOVANT GENE THERAPIES LTD (NASDAQ), SYNLOGIC INC (NASDAQ), GLYCOMIMETICS INC (NASDAQ), LEXICON PHARMACEUTICALS INC (NASDAQ), LINEAGE CELL THERAPEUTICS INC (NYSE American), STRONGBRIDGE BIOPHARMA PLC (NASDAQ), ENZO BIOCHEM INC (NYSE), ANAVEX LIFE SCIENCES CORPORATION (NASDAQ), AVALON GLOBOCARE CORP (NASDAQ), PARATEK PHARMACEUTICALS INC (NASDAQ), ACORDA THERAPEUTICS INC (NASDAQ), UNI-BIO GROUP (HKEx), BICYCLE THERAPEUTICS PLC SPON ADS EACH REP 1 ORD SHS (NASDAQ), BBI LIFE SCI (HKEx), BIOXCEL THERAPEUTICS INC (NASDAQ), PALATIN TECHNOLOGIES INC (NYSE American), ALDEYRA THERAPEUTICS (NASDAQ), IMV INC (NASDAQ), STANDARD DIVERSIFIED INC (NYSE American), APTOSE BIOSCIENCES INC (NASDAQ), MERSANA THERAPEUTICS INC (NASDAQ), JOUNCE THERAPEUTICS INC (NASDAQ), NANTKWEST INC (NASDAQ), FORTRESS BIOTECH INC (NASDAQ), SESEN BIO INC (NASDAQ), TOCAGEN INC (NASDAQ), ENTASIS THERAPEUTICS HLDGS INC (NASDAQ), ADURO BIOTECH INC (NASDAQ), AVEO PHARMACEUTICALS INC (NASDAQ), ITERUM THERAPEUTICS PLC (NASDAQ), VERASTEM INC (NASDAQ), SAVARA INC (NASDAQ), KEZAR LIFE SCIENCES INC (NASDAQ), HARVARD BIOSCIENCE INC (NASDAQ), TIZIANA LIFE SCIENCES PLC SPON ADS EACH REPR 10 ORD SHS (NASDAQ), SUNESIS PHARMACEUTICALS INC (NASDAQ), ERYTECH PHARMA SPON ADR EACH REPR 1 ORD (NASDAQ), EDAP TMS S.A. SPON ADS EACH REPR 1 ORD SHARE (NASDAQ), FENNEC PHARMACEUTICALS INC (NASDAQ), ALPINE IMMUNE SCIENCES INC (NASDAQ), CATALYST BIOSCIENCES INC (NASDAQ), MERRIMACK PHARMACEUTICALS INC (NASDAQ), TREVENA INC (NASDAQ), ANIXA BIOSCIENCES INC (NASDAQ), NEON THERAPEUTICS INC (NASDAQ), ASLAN PHARMACEUTICALS LIMITED ADS EACH REP 5 ORD SHS (NASDAQ), ARBUTUS BIOPHARMA CORP (NASDAQ), NAVIDEA BIOPHARMACEUTICALS INC (NYSE American), SELECTA BIOSCIENCES INC (NASDAQ), CEL-SCI CORP (NYSE American), GENOCEA BIOSCIENCES INC (NASDAQ), PORT (SET), VACCINEX INC (NASDAQ), CATABASIS PHARMACEUTICALS INC (NASDAQ), COHBAR INC (NASDAQ), ORGENESIS INC (NASDAQ), OTONOMY INC (NASDAQ), EQUILLIUM INC (NASDAQ), INFINITY PHARMACEUTICALS INC (NASDAQ), ARAVIVE INC (NASDAQ), VTV THERAPEUTICS INC (NASDAQ), INFLARX N V (NASDAQ), CURIS INC (NASDAQ), MEREO BIOPHARMA GROUP PLC SPON ADS EACH REP 5 ORD SHS (NASDAQ), CHAMPIONS ONCOLOGY INC (NASDAQ), AQUABOUNTY TECHNOLOGIES INC (NASDAQ), IBIO INC (NYSE American), IDERA PHARMACEUTICALS INC (NASDAQ), VBI VACCINES INC CDA (NASDAQ), UNUM THERAPEUTICS INC (NASDAQ), CORREVIO PHARMA CORP (NASDAQ), MATINAS BIOPHARMA HOLDINGS INC (NYSE American), PLURISTEM THERAPEUTICS INC (NASDAQ), INMUNE BIO INC (NASDAQ), OPIANT PHARMACEUTICALS INC (NASDAQ), NEWLINK GENETICS CORP (NASDAQ), APPLIED GENETIC TECHNOLOGIES CORP (NASDAQ), IMMUTEP LTD SPON ADR EACH REP 100 ORD SHS (NASDAQ), VERMILLION INC (NASDAQ), SURFACE ONCOLOGY INC (NASDAQ), HEMISPHERX BIOPHARMA INC (NYSE American), OUTLOOK THERAPEUTICS INC (NASDAQ), SYNTHETIC BIOLOGICS INC (NYSE American), IVERIC BIO INC (NASDAQ), CT ENTERPRISE (HKEx), FORWARD PHARMA AS SPON ADR EACH REP 2 ORD SHS (NASDAQ), REGENT PACIFIC (HKEx), VASCULAR BIOGENICS LTD (NASDAQ), BELLICUM PHARMACEUTICALS (NASDAQ), MIRAGEN THERAPEUTICS INC (NASDAQ), ARMATA PHARMACEUTICALS INC (NYSE American), SUMMIT THERAPEUTICS PLC ADS EACH REPR 5 ORD (NASDAQ), EVOGENE LTD (NASDAQ), T2 BIOSYSTEMS INC (NASDAQ), CIDARA THERAPEUTICS INC (NASDAQ), ORGANOVO HLDGS INC (NASDAQ), LEAP THERAPEUTICS INC (NASDAQ), SEELOS THERAPEUTICS INC (NASDAQ), APTEVO THERAPEUTICS INC (NASDAQ), SENESTECH INC (NASDAQ), BIO-PATH HOLDINGS INC (NASDAQ), SELLAS LIFE SCIENCES GROUP INC (NASDAQ), PROTEOSTASIS THERAPEUTICS INC (NASDAQ), ALIMERA SCIENCES INC (NASDAQ), CELLDEX THERAPEUTICS INC (NASDAQ), INDIA GLOBALIZATION CAPITAL INC (NYSE American), SIERRA ONCOLOGY INC (NASDAQ), INNOVATE BIOPHARMACEUTICALS INC (NASDAQ), ZAFGEN INC (NASDAQ), CONTRAFECT CORP (NASDAQ), SOPHIRIS BIO INC (NASDAQ), DIAMEDICA THERAPEUTICS INC (NASDAQ), HTG MOLECULAR DIAGNOSTICS INC (NASDAQ), AZURRX BIOPHARMA INC (NASDAQ), MIDATECH PHARMA PLC SPON ADS EACH REP 20 ORD SHS(R/S) (NASDAQ), VISTAGEN THERAPEUTICS INC (NASDAQ), BIOSINO BIO-TEC (HKEx), AEVI GENOMIC MEDIC (NASDAQ), EXTRAWELL PHAR (HKEx), BIOCARDIA INC (NASDAQ), MICROBOT MEDICAL INC (NASDAQ), BIOCEPT INC (NASDAQ), SOLIGENIX INC (NASDAQ), AETERNA ZENTARIS INC (NASDAQ), CELLECTAR BIOSCIENCES INC (NASDAQ), CO DIAGNOSTICS INC (NASDAQ), VICAL INC (NASDAQ), ORAGENICS INC (NYSE American), HEAT BIOLOGICS INC (NASDAQ), FIBROCELL SCIENCE INC (NASDAQ), HISTOGENICS CORP (NASDAQ), ISORAY INC (NYSE American), PRECIPIO INC (NASDAQ), BIONANO GENOMICS INC (NASDAQ), ALTERITY THERAPEUTICS LIMITED SPON ADS EA REPR 60 ORD SHS (NASDAQ), PULMATRIX INCORPORATED (NASDAQ), TROVAGENE INC (NASDAQ), ACTINIUM PHARMACEUTICALS INC (NYSE American), CLEVELAND BIOLABS INC (NASDAQ), ANCHIANO THERAPEUTICS LTD SPON ADS EACH REP 5 ORD SHS (NASDAQ), ACHIEVE LIFE SCIENCE INC (NASDAQ), NANOVIRICIDES INC (NYSE American), TRACON PHARMACEUTICALS INC (NASDAQ), KAZIA THERAPEUTICS LIMITED SPON ADR EACH REP 10 ORD SHS (NASDAQ), DARE BIOSCIENCE INC (NASDAQ), ONCONOVA THERAPEUTICS INC (NASDAQ), Suntar Eco-City^ (SGX), NOVELION THERAPEUTICS INC (NASDAQ), IMMURON LIMITED SPON ADR EACH REPR 40 ORD SHS (NASDAQ), ATYR PHARMA INC (NASDAQ), CAPRICOR THERAPEUTICS INC (NASDAQ), NOVABAY PHARMACEUTICALS INC (NYSE American), ENDRA LIFE SCIENCES INC (NASDAQ), CONATUS PHARMACEUTICALS INC (NASDAQ), VAXART INC (NASDAQ), DIFFUSION PHARMACEUTICALS INC (NASDAQ), BENITEC BIOPHARMA LTD SPON ADR EA REPR 20 ORD (NASDAQ), ONCOLYTICS BIOTECH INC (NASDAQ), MOTIF BIO PLC ADR EACH REPR 20 SHS SPON (NASDAQ), GENETIC TECHNOLOGIES SPON ADS EA REP 600 ORD SHS(R/S) (NASDAQ), PHIO PHARMACEUTICALS CORP (NASDAQ), XTL BIOPHARMACEUTICALS LTD SPON ADS EACH REP 100 ORD SHS(POST SPLT) (NASDAQ), REXAHN PHARMACEUTICALS INC (NASDAQ), THERAPIX BIOSCIENCES LTD SPON ADR EACH REP 40 ORD (POST SPLIT) (NASDAQ), CAN FITE BIOPHARMA LTD SPON ADS EA REP 30 ORD SHS(POST REV SPL (NYSE American), CYCLACEL PHARMA IN (NASDAQ), ARCA BIOPHARMA INC (NASDAQ), XENETIC BIOSCIENCES INC (NASDAQ), ADVAXIS INC (NASDAQ), MGRC (Bursa), QT Vascular (SGX), AURIS MEDICAL HOLDING LTD (NASDAQ), HAO WEN HLDGS (HKEx), MEGASUN (Bursa), PROTEON THERAPEUTICS INC (NASDAQ), INVIVO THERAPEUTICS HOLDING CORP (NASDAQ), OPGEN INC (NASDAQ), NEURALSTEM INC (NASDAQ), PLUS THERAPEUTICS INC (NASDAQ), CELLECT BIOTECHNOLOGY LTD SPON ADR EACH REP 20 ORD SHS (NASDAQ), TRILLIUM THERAPEUTICS INC (NASDAQ)
Notes:
  1. For companies, Market Cap is based on the trading currency of the company. Industry/Index Market Cap is the average market cap for that industry/index.
  2. Industry/Index PE is calculated using (Total Market Cap/Total Earnings) of all companies in the industry/index.
  3. Industry/Index Price/NAV is calculated using (Total Market Cap/Total Shareholders' Equity) of all companies in the industry/index.
  4. Industry/Index Dividend Yield is calculated using (Total Gross Dividend/Total Market Cap) of all companies in the industry/index.
  5. For Industry/Index calculation, data for foreign currency denominated companies will be converted to the main market currency using the latest exchange rate.
  6. Industry/Index/Peers data is updated daily.
  7. Peers are sorted by market capitalisation and only details for the top 10 will be shown.

Total Shareholder Return

PeriodDividend ReceivedCapital AppreciationTotal Shareholder Return
Short Term Return 5 Days -+15.800
+7.20 %
10 Days -+17.870
+8.22 %
20 Days -+12.370
+5.55 %
Medium Term Return 3 Months -+29.060
+14.09 %
6 Months 1.203+51.300
+28.53 %
1 Year 2.481+16.250
+8.55 %
Long Term Return 2 Years 3.397+107.250
+86.41 %
3 Years 5.121+125.190
+118.35 %
5 Years 6.836+161.110
+226.37 %
Annualised Return Annualised --
+26.69 %
Notes:
  1. Total Shareholder Return (TSR) combines share price appreciation and dividends paid to show the total return to the shareholder expressed as a percentage.
  2. Script dividends are ignored in this calculation.

Price Movements

1 Year Range 173.000 - 235.655 Change From 1 Year Low +62.300 % Change From 1 Year Low (%) +36.01
Change From 1 Year High -0.355 % Change From 1 Year High (%) -0.15
2 Years Range 125.840 - 235.655 Change From 2 Years Low +109.460 % Change From 2 Years Low (%) +86.98
Change From 2 Years High -0.355 % Change From 2 Years High (%) -0.15
5 Years Range 71.040 - 235.655 Change From 5 Years Low +164.260 % Change From 5 Years Low (%) +231.22
Change From 5 Years High -0.355 % Change From 5 Years High (%) -0.15
Notes:
  1. Price movements are based on adjusted historical data.

Company Background

CSL Ltd. is a biopharmaceutical company, which engages in the manufacture, marketing, and distribution of biopharmaceutical and allied products. It operates through the CSL Behring and Seqirus segments. The CSL Behring segment provides plasma therapies and conducts early stage research on plasma and non plasma therapies. The Seqirus segment involves in the production of non-plasma biotherapeutic products and develops influenza related products. The company was founded on November 2, 1961 and is headquartered in Parkville, Australia.

Historical Price Data

Date Open High Low Close Volume VWAP
20 Aug 2019 230.000 234.660 229.550 234.450 781,211 -
19 Aug 2019 228.090 230.860 227.740 229.520 618,688 -
16 Aug 2019 226.100 229.590 226.100 227.400 833,204 -
15 Aug 2019 232.000 233.000 225.530 226.610 1,380,185 -
14 Aug 2019 230.470 235.655 229.730 234.000 2,103,209 -
13 Aug 2019 220.880 221.840 218.430 219.500 895,112 -
12 Aug 2019 221.200 222.780 220.020 222.780 624,208 -
09 Aug 2019 222.790 223.700 219.140 220.020 629,278 -
08 Aug 2019 216.800 223.000 216.800 222.790 546,659 -
07 Aug 2019 218.210 220.000 216.020 218.880 742,955 -
06 Aug 2019 217.000 220.180 215.240 217.430 1,263,900 -
05 Aug 2019 230.480 231.550 225.700 226.450 583,556 -
02 Aug 2019 231.190 233.050 230.240 232.030 602,435 -
01 Aug 2019 229.240 231.580 228.900 228.900 530,534 -
31 Jul 2019 229.900 231.230 228.710 229.620 424,187 -
30 Jul 2019 230.000 231.540 229.240 230.220 502,738 -
29 Jul 2019 227.300 229.770 226.810 228.850 716,444 -
26 Jul 2019 225.800 229.430 225.350 226.690 1,789,207 -
25 Jul 2019 224.700 228.000 224.380 228.000 1,099,425 -
24 Jul 2019 224.200 224.200 222.430 223.340 699,954 -
23 Jul 2019 221.000 223.340 220.900 222.930 550,444 -
22 Jul 2019 224.000 224.490 221.480 221.810 404,240 -
Summary
Current 2 Weeks
(07 Aug 2019 to 20 Aug 2019)		 218.210 235.655 216.020 234.450 9,154,709 -
Previous 2 Weeks
(24 Jul 2019 to 06 Aug 2019)		 224.200 235.655 216.020 217.430 8,212,380 -
4 Weeks from
(26 Jun 2019 to 23 Jul 2019)		 215.390 235.655 214.410 222.930 12,127,534 -
View All Historical Data

More Information Available

More information is available to our subscribers, including:

  • Market Moving News from Dow Jones Newswires
  • Consensus Estimates
  • Dividend/Distribution History
  • Financial Summary with Financial Period Comparison
  • Comprehensive Financial Ratios(ROA, ROE, Price/Revenue, Net Earnings Margin, Current Ratio, Debt to Equity Ratio etc)
  • Events Calendar for Results Announcements, Ex-Dates etc
  • Insider Buying and Selling Report

If you are an existing subscriber, please login. If not, read up on what you are missing out in our Help Centre and join us as a subscriber.

Disclaimer:

While reasonable efforts have been taken to ensure that the calculations performed by the features of this site are reliable, the features are provided on the basis that:-

  1. no liability is accepted for any errors or inaccuracies resulting from your use of these features;
  2. many of the data inputs (including share prices) are obtained from third party sources for which we assume no responsibility.